Verastem (VSTM) Cash from Operations (2011 - 2026)
Verastem (VSTM) posted quarterly Cash from Operations of 52116000.0 for Q1 2026, down 34.75% year-over-year from 79871549.22 in Q1 2025, and down 73.99% quarter-over-quarter from 29954000.0 in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) Cash from Operations (2011 - 2026) Analysis & Trends
Verastem's Cash from Operations history runs 16 years deep, the most recent figure standing at 52116000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 34.75% year-over-year to 52116000.0; the TTM figure through Mar 2026 stood at 150949000.0 (down 31.1% YoY), while the FY2025 annual figure was 137509000.0, down 31.25% from the prior year.
- Cash from Operations for Q1 2026 stood at 52116000.0, down from 29954000.0 in the prior quarter.
- The five-year high for Cash from Operations was 12694000.0 in Q2 2022, with the low at 52116000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 25099000.0 (2024), against an average of 26148764.71.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 78.63% in 2023, then gained 15.44% in 2024.
- Verastem's Cash from Operations stood at 16616000.0 in 2022, then slumped by 78.63% to 29681000.0 in 2023, then increased by 15.44% to 25099000.0 in 2024, then dropped by 19.34% to 29954000.0 in 2025, then plunged by 73.99% to 52116000.0 in 2026.
- Business Quant data shows VSTM's Cash from Operations at 52116000.0 in Q1 2026, 29954000.0 in Q4 2025, and 36216000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Verastem | 815.95 Mn | 679.59 Mn | 36.32 Mn | -43.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.91 Mn |
| Mar 31, 2026 | -52.12 Mn |
| Dec 31, 2025 | -29.95 Mn |
| Sep 30, 2025 | -36.22 Mn |
| Jun 30, 2025 | -32.66 Mn |
| Mar 31, 2025 | -38.68 Mn |
| Dec 31, 2024 | -25.10 Mn |
| Sep 30, 2024 | -23.80 Mn |
| Jun 30, 2024 | -27.57 Mn |
| Mar 31, 2024 | -28.31 Mn |
| Dec 31, 2023 | -29.68 Mn |
| Sep 30, 2023 | -16.59 Mn |
| Jun 30, 2023 | -19.90 Mn |
| Mar 31, 2023 | -20.29 Mn |
| Dec 31, 2022 | -16.62 Mn |
| Sep 30, 2022 | -15.08 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -19.28 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -10.83 Mn |